Identification of a Biomarker Signature to Predict the Need for Chemotherapy in Patients With Hormone Receptor Positive Breast Cancer

被引：0
|
作者：
Korf, U. [1 ]
Sonntag, J. [1 ]
Bender, C. [1 ]
Wiemann, S. [1 ]
Aulmann, S. [2 ]
Sinn, P. [2 ]
Burwinkel, B. [2 ]
Schneeweiss, A. [3 ]
Beissbarth, T. [4 ]
机构：
[1] German Canc Res Ctr, Heidelberg, Germany
[2] Univ Clin Heidelberg, Heidelberg, Germany
[3] Natl Ctr Tumor Dis Heidelberg, Gynecol Oncol Sect, Heidelberg, Germany
[4] Univ Med Ctr Gottingen, Gottingen, Germany
来源：
EUROPEAN JOURNAL OF CANCER | 2012年 / 48卷
关键词：
D O I：
10.1016/S0959-8049(12)71480-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
847
引用
收藏
页码：S203 / S204
页数：2
相关论文
共 50 条
  • [21] A mathematical model to predict for response to neoadjuvant hormone therapy in elderly patients with hormone receptor (HR)-positive breast cancer.
    Zoubir, M.
    Bouaziz, J.
    Rouzier, R.
    Garbay, J. R.
    Spielmann, M.
    Conforti, R.
    Bongain, A.
    Mathieu, M. C.
    Vielh, P.
    Bourgier, C.
    Lallement, M.
    Andre, F.
    Delaloge, S.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S54 - S54
  • [22] Plasma Proteome Signature to Predict the Outcome of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
    Gwark, Sungchan
    Ahn, Hee-Sung
    Yeom, Jeonghun
    Yu, Jiyoung
    Oh, Yumi
    Jeong, Jae Ho
    Ahn, Jin-Hee
    Jung, Kyung Hae
    Kim, Sung-Bae
    Lee, Hee Jin
    Gong, Gyungyub
    Lee, Sae Byul
    Chung, Il Yong
    Kim, Hee Jeong
    Ko, Beom Seok
    Lee, Jong Won
    Son, Byung Ho
    Ahn, Sei Hyun
    Kim, Kyunggon
    Kim, Jisun
    CANCERS, 2021, 13 (24)
  • [23] Is controlled ovarian stimulation safe in patients with hormone receptor-positive breast cancer receiving neoadjuvant chemotherapy?
    Benvenuti, C.
    Laot, L.
    Grinda, T.
    Lambertini, M.
    Pistilli, B.
    Grynberg, M.
    ESMO OPEN, 2024, 9 (02)
  • [24] Clinical outcomes of single versus double hormone receptor positive breast cancer patients treated with neoadjuvant chemotherapy
    Raphael, J.
    Nofech-Mozes, S.
    Trudeau, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [25] Adjuvant Dose-Dense Chemotherapy in Hormone Receptor-Positive Breast Cancer
    Metzger Filho, Otto
    Ballman, Karla
    Campbell, Jordan
    Liu, Minetta
    Ligibel, Jennifer
    Watson, Mark
    Chen, Eveline
    Du, Lili
    Stover, Daniel
    Carey, Lisa
    Partridge, Ann
    Kirshner, Jeffrey
    Muss, Hyman
    Hudis, Clifford
    Winer, Eric P.
    Norton, Larry
    Symmans, W. Fraser
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (10)
  • [26] Hormone receptor-positive early breast cancer: controversies in the use of adjuvant chemotherapy
    Montemurro, Filippo
    Aglietta, Massimo
    ENDOCRINE-RELATED CANCER, 2009, 16 (04) : 1091 - 1102
  • [27] Chemotherapy use for hormone receptor-positive, node-negative breast cancer
    Hassett, M. J.
    Hughes, M. E.
    Niland, J. C.
    Edge, S. B.
    Theriault, R. L.
    Wong, Y.
    Wilson, J.
    Carter, B. W.
    Blayney, D. W.
    Weeks, J. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [28] Race and Hormone Receptor-Positive Breast Cancer Outcomes in a Randomized Chemotherapy Trial
    Sparano, Joseph A.
    Wang, Molin
    Zhao, Fengmin
    Stearns, Vered
    Martino, Silvana
    Ligibel, Jennifer A.
    Perez, Edith A.
    Saphner, Tom
    Wolff, Antonio C.
    Sledge, George W., Jr.
    Wood, William C.
    Davidson, Nancy E.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (05): : 406 - 414
  • [29] A balancing act for breast cancer? Everolimus for hormone receptor positive patients
    Wheeler, Stephanie B.
    Reeder-Hayes, Katherine
    Meyer, Anne-Marie
    TRANSLATIONAL CANCER RESEARCH, 2012, 1 (02) : 109 - 112
  • [30] A 3-gene biomarker signature to predict response to taxane-based neoadjuvant chemotherapy in breast cancer
    Kallarackal, Jim
    Burger, Florian
    Bianco, Stefano
    Romualdi, Alessandro
    Schad, Martina
    PLOS ONE, 2020, 15 (03):
12345